David A. Roth
2022 - Syros Pharmaceuticals
In 2022, David A. Roth earned a total compensation of $1.8M as Chief Medical Officer at Syros Pharmaceuticals, a 9% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,000 |
|---|---|
| Option Awards | $380,317 |
| Salary | $497,538 |
| Stock Awards | $699,258 |
| Other | $1,980 |
| Total | $1,759,093 |
Roth received $699.3K in stock awards, accounting for 40% of the total pay in 2022.
Roth also received $180K in non-equity incentive plan, $380.3K in option awards, $497.5K in salary and $2K in other compensation.
Rankings
In 2022, David A. Roth's compensation ranked 1,961st out of 5,760 executives tracked by ExecPay. In other words, Roth earned more than 66.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,961 out of 5,760 | 66th |
Division Manufacturing | 1,045 out of 3,136 | 67th |
Major group Chemicals And Allied Products | 443 out of 1,422 | 69th |
Industry group Drugs | 406 out of 1,323 | 69th |
Industry Pharmaceutical Preparations | 294 out of 969 | 70th |
Source: SEC filing on April 21, 2023.
Roth's colleagues
We found two more compensation records of executives who worked with David A. Roth at Syros Pharmaceuticals in 2022.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019